Roche consolidates mGluR5 antagonist position with Seaside alliance for autism
This article was originally published in Scrip
Roche has strengthened its mGluR5 antagonist portfolio by entering a collaboration with Seaside Therapeutics. Seaside will license its patents covering the use of mGluR5 antagonists for the treatment of neurodevelopmental disorders exclusively to Roche. Roche will pursue these compounds for the treatment of fragile X syndrome (FXS) and autism spectrum disorders (ASD). Seaside's mGluR5 antagonist assets include STX107, which completed a Phase I study for FXS in 2010 but has been sitting on the backburner while the company focuses on its GABA-B agonist programme.